TCL Archive Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer July 31, 2009
TCL Archive Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events June 28, 2013